Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0PPMSF
ADC Name	WO2020063673A1 ADC-8
Synonyms	WO2020063673A1_ADC 8 Click to Show/Hide
Organization	Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Drug Status	Investigative
Indication	In total 4 Indication(s) Astrocytoma [ICD11:2F36] Investigative Kidney cancer [ICD11:2C90-2C91] Investigative Melanoma [ICD11:2C30] Investigative Non-small cell lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	6.33
Structure
	3D MOL	2D MOL
Antibody Name	Anti-CD276 mAb h1702DS		Antibody Info
Antigen Name	CD276 antigen (CD276)		Antigen Info
Payload Name	Undisclosed
Linker Name	WO2020063673A1_ADC-8 linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 47.7	%	U-87MG cells	Glioblastoma
Tumor Growth Inhibition value (TGI)	≈ 89.8	%	U-87MG cells	Glioblastoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 47.70% (Day 22)	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of U87MG cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.80% (Day 22)	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of U87MG cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

References

Ref 1	Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof; 2020-04-02.